Figures computed from official regulatory filings — .
Analysttarget 8.75 USD (+2187400%) · consensus 3/5 · 0 buy · 3 hold · 0 sell
Ownershipinsiders 0% · institutions 0% · short 3.8% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Syros Pharmaceuticals, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
32 buys56 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details | |
|---|---|---|---|---|---|
| Simonian Nancy A | Sell | $10K | SEC | ||
| Simonian Nancy A |
| Sell |
| $36.4K |
| SEC |
| Roth David | Sell | $2.4K | SEC |
| Stephens Kristin | Sell | $7.9K | SEC |
| Quirk Gerald E | Sell | $10.3K | SEC |
| Haas Jason | Sell | $28.9K | SEC |
| Chee Conley | Sell | $27K | SEC |
| Roth David | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Haas Jason | Other | $11.8K | SEC |
| Roth David | Other | $14.2K | SEC |
| Chee Conley | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simonian Nancy A | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Haas Jason | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Haas Jason | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Chee Conley | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Stephens Kristin | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Chee Conley | Other | $18.2K | SEC |
| Stephens Kristin | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Simonian Nancy A | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Roth David | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Stephens Kristin | Other | $12.8K | SEC |
| Quirk Gerald E | Exercise | n/a (No price was disclosed in the filing) | SEC |
| Quirk Gerald E | Other | $6.5K | SEC |
| Quirk Gerald E | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| AKKARAJU SRINIVAStrack record | ExerciseD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |